(NVCN) today provided an update on its clinical program for the Tiara™ ("Tiara") valve, a self-expanding mitral bioprosthesis for transcatheter implantation in patients with Mitral Regurgitation ("MR"), one of the most prevalent valvular heart diseases in western countries. MR is often severe and can lead to heart failure and death.
The new status, valid for one year and renewable annually, enables German hospitals to negotiate reimbursement coverage for Neovasc Reducer therapy under the country's health insurance system.
•CE-Mark'd Reducer is used to treat refractory angina, a painful condition caused by inadequate blood flow to the heart despite standard revascularization or cardiac drug treatments. Neovasc (NASDAQ:NVCN) |
Mesothelioma BlogArchives
September 2020
Categories
All
|